Whalesbook
Clean Science's Q4FY26 results showed a stark contrast: its specialty segments are booming, while older product lines are still facing tough competition and demand issues. The company is investing in future growth and integration, but its expansion timelines and profitability are under scrutiny, balanced against the strong HALS performance and a cautious market outlook.
HALS Momentum and New Capacity
The Hindered Amine Light Stabilizers (HALS) segment was a major growth driver, achieving its highest quarterly revenue ever and turning EBITDA positive for the first time, with profits estimated between ₹70-80 million. This boost came from a better product mix and increased export demand, with volumes reaching about 1,000 metric tons in Q4FY26 and factory usage at 40% by March. Management expects HALS growth to continue, supported by new, higher-grade products. The company is also integrating backward into key HALS materials by repurposing its DHTT plant. Additionally, the Hydroquinone (HQ) and Catechol plant, which started up in December 2025, is expected to ramp up production gradually in the coming quarters.
Legacy Products Face Pressure
Revenue from established product lines declined significantly. The company's Q4FY26 standalone revenue dropped 19% year-on-year to ₹197 crore. For the full fiscal year 2026, standalone Profit After Tax (PAT) fell 14% year-on-year to ₹251 crore on ₹815 crore in revenue. This downturn stems from lower sales volumes of older products, worsened by steep drops in end-product prices due to intense competition from China. Market conditions remain difficult, with weak demand and trade pressures, particularly affecting the pharma and agro intermediates segment, which saw a 32% drop in revenue quarter-on-quarter.
Expansion Delays and Valuation
Commercialization of a new capacity addition, Performance Chemical 2, is now delayed to September 2026 because of staff shortages. This setback impacts the company's expansion plans. Clean Science currently trades at about 35 times its trailing twelve-month earnings, placing it within the specialty chemicals sector. This valuation is lower than peers like Aarti Industries (49.2x P/E) and Navin Fluorine (53.3x P/E), but higher than Vinati Organics (30.36x P/E). Working capital days have also increased significantly, from 144 to 242 days over the past year, pointing to potential cash flow issues.
Key Concerns
The company's reliance on older products faces major competitive threats. Fierce competition from China has consistently squeezed end-product prices and volumes, evident in recent quarters. While HALS is promising, the long-term profitability of established categories is uncertain, especially amid global economic instability and potential raw material price swings. Promoter holding has also dropped by 27.2% in the last three years. The company saw a 15%/17% revenue/PAT decline between FY23 and FY24 due to global inventory reduction. The delay in Performance Chemical 2 due to staffing issues raises questions about operational execution speed. The current P/E multiple seems less appealing considering the revenue decline in core areas and execution risks, especially when compared to Vinati Organics.
Analyst View
Prabhudas Lilladher maintains a 'HOLD' rating on Clean Science, with a target price of ₹846. This target is based on 25 times projected FY28 earnings per share. The rating reflects caution regarding market volatility and potential lower prices for legacy products, even as future capacity additions are expected to drive growth. While some analysts previously upgraded the stock, recent sentiment appears mixed with some downgrades. The Indian specialty chemicals sector overall is expected to grow, benefiting from domestic industrialization and the 'China Plus One' strategy, though global economic uncertainties remain a factor.